Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting
Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…Abstract Number: 677 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…Abstract Number: 678 • 2017 ACR/ARHP Annual Meeting
Systemic Hypertension Is Associated with Presence of Vascular Injury on Lupus Nephritis Renal Biopsies: A Retrospective Cohort Study
Background/Purpose: Vascular injury in lupus nephritis is often described on renal biopsy, but its clinical correlates are not well understood. Recent evidence suggests it may…Abstract Number: 679 • 2017 ACR/ARHP Annual Meeting
Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE
Background/Purpose: Type I interferon (IFN-I) has a crucial role in the pathogenesis and activity of Systemic Lupus Erythematosis (SLE). IFN-I targeted therapies are currently in…Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…Abstract Number: 682 • 2017 ACR/ARHP Annual Meeting
Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations
Background/Purpose: Abnormal activation of the complement system is emerging as a useful biomarker in the evaluation of patients presenting symptoms of autoimmune rheumatic diseases. We…Abstract Number: 683 • 2017 ACR/ARHP Annual Meeting
The Presence of Anti-Ro and Anti-La Antibodies Is Associated with Tubulointerstitial Damage in Lupus Nephritis
Background/Purpose: Moderate-to-severe tubulointerstitial damage (TID) is associated with poor renal outcomes in lupus-related kidney disease, independent of glomerular pathology1. Unlike glomerular damage, TID is not…Abstract Number: 684 • 2017 ACR/ARHP Annual Meeting
ANTI-RO52 KDa and ANTI-RO60 KDa Analysis in Systemic LUPUS Erythematous Patients to Detect ANTI-RO False-Negatives
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption with autoantibodies production. One of the upregulated autoantibodies is the specific…Abstract Number: 685 • 2017 ACR/ARHP Annual Meeting
Anti-C1q Antibodies and Disease Activity in a Multi-Ethnic Lupus Cohort
Background/Purpose: Anti-C1q antibodies (C1Q Ab) are observed in 30-60% of patients with Systemic Lupus Erythematosus (SLE). A number of studies have shown that the presence…
ACR Meeting Abstracts